NCT06629597View on ClinicalTrials.gov

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

YL201

YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.

DRUG

Docetaxel

Docetaxel will be administered intravenously at 75 mg/m2 on Day 1 of each 3-week cycle.

DRUG

Capecitabine

Capecitabine will be administered orally at 1000 mg/m2 twice a day (BID) on Days 1 to 14 of each 3-week cycle

DRUG

Gemcitabine

Gemcitabine will be administered intravenously at 1000 mg/m2 on Day 1 and 8 of each 3-week cycle

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

MediLink Therapeutics (Suzhou) Co., Ltd.

INDUSTRY